| Cat.No. | Name | Information |
|---|---|---|
| M1959 | Oseltamivir | Oseltamivir is a potent and selective inhibitor of influenza virus neuraminidase enzyme. |
| M5055 | Peramivir | Peramivir is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M1707 | Entecavir Monohydrate | Entecavir Hydrate is a class of antiviral compounds. |
| M3357 | Telbivudine | Telbivudine (Epavudine) is an orally active, potent antiviral inhibitor of hepatitis B virus (HBV) replication. Telbivudine is an antiviral compound used in hepatitis B research. |
| M1695 | Cidofovir | Cidofovir (Vistide) is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis. |
| M4718 | Dendrobine | Dendrobine is an alkaloid isolated from Dendrobium nobile. Dendrobine has antiviral activity against influenza A virus, IC50 values for A/FM-1/1/47 (H1N1), A/Puerto Rico/8/34 H274Y (H1N1) and A/Aichi/2/68 (H3N2) were 3.39 μM, 2.16 μM and 5.32 μM, respectively. |
| M3222 | Peramivir Trihydrate | Peramivir Trihydrate is a trihydrate of the anti-infection agent peramivir (RWJ-270201,BCX-1812) which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM. |
| M4789 | Isoscopoletin | Isoscopoletin (6-Hydroxy-7-methoxycoumarin) is an active ingredient in artemisia argyi leaves. Isoscopoletin showed significant inhibition of cell proliferation, with IC50 values of 4.0 μM and 1.6 μM against human CCRF-CEM leukemia cells and CEM/ADR5000 drug-resistant subline, respectively. Isoscopoletin (6-Hydroxy-7-methoxycoumarin) has the activity of inhibiting HBV replication. |
| M10082 | Amodiaquine | Amodiaquine is a 4-aminoquinoline compound related to chloroquine, used as an antimalarial and anti-inflammatory agent. |
| M7775 | 3-Deazaadenosine | 3-Deazaadenosine is an inhibitor of S-adenosylhomocysteine hydrolase, with a Ki of 3.9 µM, possesses antiviral activity inhibitor of leukocyte adhesion to TNF-treated endothelial cells. |
| M27815 | 3-Deoxysappanchalcone | 3-Deoxysappanchalcone is a naturally-occurring chalcone compound isolated from Caesalpinia sappan L. (Leguminosae), which possesses anti-allergic, antiviral, anti-inflammatory and antioxidant activities. 3-Deoxysappanchalcone exerts anti-inflammatory activity via induce heme oxygenase-1 (HO-1) expression by activating the AKT/mTOR pathway in murine macrophages. 3-Deoxysappanchalcone also exhibits anti-influenza virus activity (H3N2, IC50 = 1.06 μM). |
| M27781 | Morphothiadin | Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir-resistant HBV with an IC50 of 12 nM. |
| M27768 | GRL-0496 | GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC50 of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC50 of 6.9 μM. |
| M27626 | HZ-1157 | HZ-1157 inhibits HCV NS3/4A protease with an IC50 of 1.0 μmol/L. HZ-1157 (4a) has a high dengue virus inhibitory activity (EC50 = 0.15 μM) and is a relatively nontoxic (CC50 > 10 μM) dengue antiviral agent. |
| M25320 | Anti-MERS-D12 mAb | Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding. |
| M25319 | Anti-MERS-3A1 mAb | Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor. |
| M25318 | Anti-MERS-2E6 mAb | Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells. |
| M25317 | Anti-SARS-80R mAb | Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells. |
| M25316 | Anti-Spike-RBD Single Domain mAb | Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity. |
| M25315 | Anti-Spike-RBD mAb | Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment. |
| M25297 | Rafivirumab | Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails. |
| M25238 | Pagibaximab | Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis. |
| M25236 | Libivirumab | Libivirumab (17.1.41) is a humanized anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively. |
| M25197 | Ogalvibart | Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model. |
| M25189 | Lomtegovimab | Lomtegovimab (BI 767551) is a humanized anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19. |
| M25188 | Rimteravimab | Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2. |
| M25186 | Adintrevimab | Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential. |
| M25184 | Romlusevimab | Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). |
| M25183 | Amubarvimab | Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants. |
| M25174 | Fiztasovimab | Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
